Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

por Lisenko, K., Dingeldein, G., Cremer, M., Kriegsmann, M., Ho, A. D., Rieger, M., Witzens-Harig, M.
Publicado 2017

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

por Lisenko, K., McClanahan, F., Schöning, T., Schwarzbich, M. A., Cremer, M., Dittrich, T., Ho, A. D., Witzens-Harig, M.
Publicado 2016

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

por Rule, S, Jurczak, W, Jerkeman, M, Rusconi, C, Trneny, M, Offner, F, Caballero, D, Joao, C, Witzens-Harig, M, Hess, G, Bence-Bruckler, I, Cho, S-G, Thieblemont, C, Zhou, W, Henninger, T, Goldberg, J, Vermeulen, J, Dreyling, M
Publicado 2018